Patient access and support

XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Comprehensive support to help your patients access treatment

TerSera SupportSource offers coverage, access, and one-on-one nursing support, including financial assistance for eligible patients.

Contact TerSera SupportSource with questions

Phone

1-844-XERMELO (937-6356)

Hours

Monday–Friday, 9 AM to 6 PM ET

Coverage support

End-to-end navigating of patients' insurance with consistent visibility — to help them start and stay on XERMELO

Hr line

TerSera SupportSource can aid in:

Verifying patients' specific health plan coverage
Providing information regarding prior authorization (PA) requirements
Identifying patients' possible out-of-pocket responsibilities
Educating you and your patients about the appeals process if coverage is denied

Icon of 2 hands palms out holding a heart

Patient access support

Helping eligible XERMELO patients access the medication they need

Hr line

TerSera SupportSource can help with the following patient support services:

Co-pay card: Eligible, commercially insured patients may reduce out-of-pocket XERMELO prescription costs with easy-to-initiate co-pay enrollment and information on financial support*
Financial assistance: Eligible patients may receive referrals to independent assistance foundations
Patient Assistance Program: Eligible patients who establish financial need and do not have insurance coverage may receive XERMELO at no cost through the program. Terms and conditions apply

For eligible commercially insured patients, the co-pay card is subject to an annual limit. Patients are not eligible if prescriptions are paid for by any state or other federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA or DOD or TRICARE, or where prohibited by law. Additional terms and conditions apply.

Find the TerSera SupportSource enrollment form and other helpful forms, checklists, sample letters, and more.

View resources

Icon of telephone with speech bubble above it

Specialty pharmacy support

TerSera SupportSource, with our preferred specialty pharmacy, Biologics.McKesson.com, will coordinate with you, your patients, nurses, and office staff to ensure everyone has the most up-to-date prescription information.

Three ways to prescribe:

eScribe

Pharmacy Name: Biologics
NCPDP: 3430369
NPI: 1487640314

Fax

(800) 823-4506

Phone

(800) 850-4306

TerSera NurseSupport logo

TerSera NurseSupport offers one-on-one support for XERMELO patients

Your patients may connect with one of our Clinical Nurse Educators (CNEs) for questions and more:

Starting medication: Help patients understand XERMELO and what to expect
Advocacy connections: Connect patients with helpful advocacy resources
Disease education: Teach patients about carcinoid syndrome diarrhea (CSD) and how it works in the body
Nutrition education: Help patients understand the relationship between diet and CSD

When patients talk to a CNE, they can ask about the Find Food You Love book. CNEs can send them a copy for free! It’s filled with 100 pages of easy-to-follow dietary information and recipes designed to help those with CSD.

Note: TerSera NurseSupport is only available to patients who have been prescribed XERMELO. Our nurses can share general information about carcinoid syndrome diarrhea but cannot provide medical advice on a patient's specific condition.

Actor portrayals.

Request a representative

Get more information about XERMELO and resources to support your patients.

Request a rep

How XERMELO works

Hr line

See how XERMELO and SSAs work together.

Explore MOA

About CSD

Hr line

Find questions about refractory CSD symptoms to ask your patients already on SSA therapy.

Learn about CSD

Practice resources

Hr line

Download helpful forms, checklists, sample letters, and more.

View resources

Important Safety Information and Indication

Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.

Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.

Indication

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

Please see accompanying Full Prescribing Information.

Important Safety Information and Indication

Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.

Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.

Indication

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

Please see accompanying Full Prescribing Information.

Patient access and support

Comprehensive support to help your patients access treatment

Contact TerSera SupportSource with questions

Phone

Hours

Coverage support

End-to-end navigating of patients' insurance with consistent visibility — to help them start and stay on XERMELO

Patient access support

Helping eligible XERMELO patients access the medication they need

Specialty pharmacy support

Three ways to prescribe:

eScribe

Fax

Phone

TerSera NurseSupport offers one-on-one support for XERMELO patients

Request a representative

How XERMELO works

About CSD

Practice resources

Important Safety Information and Indication

Indication

Important Safety Information and Indication

Indication

Attention

Healthcare Professionals

Healthcare Professionals

NPI lookup

Search results

No results found